ACE2 shows tremendous promise in the treatment of pulmonary arterial hypertension (PAH). It corrects many of the molecular defects caused by the most common heritable cause of disease, BMPR2 mutation. It has reversed disease in a variety of animal models of PAH, including heritable, hypoxic, and inflammatory models. We have tested it acutely in human idiopathic PAH patients, and shown a variety of hemodynamic and molecular improvements, including a 40% improvement in cardiac output with associated reduction in pulmonary vascular resistance. Unfortunately, because of difficulties with both synthesis and delivery, it will be difficult to translate to common use. Understanding key mediators of its effect is thus the primary barrier to effective translation of this extraordinarily promising intervention. The proposed studies will identify the key molecular mechanisms of downstream effect of ACE2 in the context of PAH, in regulation of the cytoskeleton (aim 1), metabolism (aim 2), and improvements in right ventricle function in the heart (aim 3). The unifying hypothesis to these aims is that ACE2?s therapeutic effect is primarily through MAS1- mediated correction of cytoskeletal defects caused by suppressed BMPR2. These defects include cell-cell junctions, mitochondrial dynamics, and regulation of eNOS. The project makes use of genetic mouse models, including a new far-red reporter mouse which allows non-invasive imaging of heart stress, patient-derived endothelial precursor cells, our new artificial arteriole system which accurately reproduces pulse pressure, stiffness, flow, and shear in a cell culture system, thus combining human, mouse, and new cell culture systems to answer these questions.

Public Health Relevance

ACE2 shows tremendous promise in interventions against the molecular etiology of PAH, in cells, animals, and in our early human trials, but it will be difficult to bring to clinic because of difficulties in both synthesis and delivery. By the end of the proposed studies, we will understand the mechanisms by which ACE2 is improving both pulmonary vascular and right ventricular function, and we will have identified the molecular pathways by which these improvements are enacted. This will allow for the efficient design of small molecule interventions that target these critical pathways, and for better understanding of exactly which elements of PAH (vasoreactive, cytoskeletal, metabolic, oxidative stress, calcium signaling) are being corrected.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL095797-10
Application #
9594536
Study Section
Respiratory Integrative Biology and Translational Research Study Section (RIBT)
Program Officer
Xiao, Lei
Project Start
2019-03-01
Project End
2023-02-28
Budget Start
2019-03-01
Budget End
2020-02-28
Support Year
10
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
West, James D; Carrier, Erica J (2018) Precision Modeling of Pulmonary Hypertension Pathology with Induced Pluripotent Stem Cell-derived Cells. Am J Respir Crit Care Med 198:154-155
Rathinasabapathy, Anandharajan; Bryant, Andrew J; Suzuki, Toshio et al. (2018) rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling. Front Physiol 9:271
Suzuki, Toshio; Carrier, Erica J; Talati, Megha H et al. (2018) Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 314:L118-L126
Rathinasabapathy, Anandharajan; Horowitz, Alana; Horton, Kelsey et al. (2018) The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Front Physiol 9:180
Hemnes, Anna R; Rathinasabapathy, Anandharajan; Austin, Eric A et al. (2018) A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J 51:
Sakurai-Iesato, Yoriko; Kawata, Naoko; Tada, Yuji et al. (2017) The Relationship of Bone Mineral Density in Men with Chronic Obstructive Pulmonary Disease Classified According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Combined Chronic Obstructive Pulmonary Disease (COPD) Assessment System. Intern Med 56:1781-1790
Copeland, Courtney A; Han, Bing; Tiwari, Ajit et al. (2017) A disease-associated frameshift mutation in caveolin-1 disrupts caveolae formation and function through introduction of a de novo ER retention signal. Mol Biol Cell 28:3095-3111
Austin, Eric D; West, James; Loyd, James E et al. (2017) Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing. Am J Respir Crit Care Med 195:23-31
Trammell, Aaron W; Talati, Megha; Blackwell, Thomas R et al. (2017) Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension. Pulm Circ 7:624-634
Pickworth, Josephine; Rothman, Alexander; Iremonger, James et al. (2017) Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. Pulm Circ 7:768-776

Showing the most recent 10 out of 52 publications